Summary
Stryker Corporation's 2024 10-K filing highlights a year of robust growth and strategic acquisitions, underscoring its position as a global leader in medical technologies. The company reported a 10.2% increase in net sales, reaching $22.595 billion, driven by strong performance across both its MedSurg and Neurotechnology (up 11.1%) and Orthopaedics (up 8.9%) segments. This growth was fueled by increased unit volumes and, to a lesser extent, higher pricing, demonstrating resilience in a dynamic healthcare market. The company also completed several strategic acquisitions totaling $1.628 billion, further expanding its product portfolios and market reach. Financially, Stryker maintained healthy profitability with a gross profit margin of 63.9%. However, net earnings saw a slight decrease to $2.993 billion from $3.165 billion in the prior year, partly due to significant goodwill impairments related to its Spine business, amounting to $456 million, and a $362 million loss recognized on assets held for sale within the Spinal Implants business. Despite these charges, operating income remained strong. The company continued its commitment to capital allocation, investing in acquisitions, paying $1.219 billion in dividends, and maintaining a strong liquidity position with $3.743 billion in cash, cash equivalents, and marketable securities.
Financial Highlights
51 data points| Revenue | $22.59B |
| Cost of Revenue | $8.15B |
| Gross Profit | $14.44B |
| R&D Expenses | $1.47B |
| SG&A Expenses | $7.68B |
| Operating Expenses | $10.75B |
| Operating Income | $3.69B |
| Interest Expense | $396.00M |
| Net Income | $2.99B |
| EPS (Basic) | $7.86 |
| EPS (Diluted) | $7.76 |
| Shares Outstanding (Basic) | 381.00M |
| Shares Outstanding (Diluted) | 385.60M |
Key Highlights
- 1Stryker reported a 10.2% year-over-year increase in net sales, reaching $22.595 billion, indicating strong market demand and execution.
- 2Both major segments, MedSurg and Neurotechnology (11.1% growth) and Orthopaedics (8.9% growth), contributed to the top-line expansion.
- 3The company made significant strategic investments in acquisitions, totaling $1.628 billion, aimed at enhancing its product offerings and market presence.
- 4Despite overall sales growth, net earnings decreased to $2.993 billion due to substantial goodwill impairments ($456 million) and a loss on assets held for sale ($362 million) within the Spine business.
- 5Gross profit margin remained robust at 63.9%, demonstrating effective cost management and pricing power.
- 6Stryker maintained a strong financial position with $3.743 billion in cash, cash equivalents, and marketable securities and a commitment to returning capital to shareholders through dividends ($1.219 billion paid).
- 7The company is actively managing its product portfolio, evidenced by the reclassification and planned sale of its US Spinal Implants business.